Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, Wandert T, Ganser A, Atzpodien J
Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany.
Br J Cancer. 1999 Mar;79(7-8):1182-4. doi: 10.1038/sj.bjc.6690189.
Interleukin 10 (IL-10) is an immunosuppressive factor and has been detected in tumour cell cultures of renal cell carcinoma and of malignant melanoma. IL-10 has been described as a cytokine of the Th2 response; it is able to suppress antigen-presenting cells (APCs) and may lead to down-regulation of HLA class I and II molecules on dendritic cells and to anergy of T-lymphocytes. We evaluated pretreatment serum levels of soluble IL-10 and various clinical parameters to determine their prognostic value in 80 advanced renal cell carcinoma patients seen at our institution between May 1990 and April 1996. For statistical evaluation we used both univariate and multivariate Cox proportional hazards models. An elevated pretreatment serum level of IL-10 was a statistically independent predictor of unfavourable outcome (P < 0.0028), in addition to the well-known clinical and biochemical risk factors. These data support risk stratification for future therapeutic trials and identify a predictor which needs to be validated in prospective studies and may potentially influence decision making in palliative management of patients with metastatic renal cell carcinoma. These data also suggest a potential role of IL-10 in the development of advanced renal cell carcinoma and in the future design of therapeutic strategies.
白细胞介素10（IL-10）是一种免疫抑制因子，已在肾细胞癌和恶性黑色素瘤的肿瘤细胞培养物中检测到。IL-10被描述为Th2反应的细胞因子；它能够抑制抗原呈递细胞（APC），并可能导致树突状细胞上HLA I类和II类分子的下调以及T淋巴细胞的无反应性。我们评估了80例1990年5月至1996年4月在我们机构就诊的晚期肾细胞癌患者的预处理血清可溶性IL-10水平和各种临床参数，以确定它们的预后价值。为了进行统计评估，我们使用了单变量和多变量Cox比例风险模型。除了众所周知的临床和生化风险因素外，预处理血清IL-10水平升高是不良预后的统计学独立预测因素（P < 0.0028）。这些数据支持未来治疗试验的风险分层，并确定了一个需要在前瞻性研究中验证的预测因素，该因素可能会影响转移性肾细胞癌患者姑息治疗的决策。这些数据还表明IL-10在晚期肾细胞癌的发展和未来治疗策略设计中可能发挥的作用。
